Skip to main content
OpenTrials
Completed

NCT Number: NCT04382963

Stroke Prevention in the Wisconsin Native American Population

This project will develop a "Stroke Awareness Team" including training of Oneida Health Service Coaches working in partnership with the UW team for a population-based health awareness program. This team will develop a series of Oneida Nation Healthy Living and Stroke Awareness Events (from now on health events) to provide education as to the severity of the problem as well as our standard therapies for lifestyle change and risk factor avoidance. This will include education of the healthy members of the tribe including the children to identify signs of stroke and TIA in their elders as well as to develop healthy lifestyles at the earliest of ages to influence the elders to modify their risks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

55 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Wisconsin-Madison, Madison, Wisconsin, United States

Loading trial locations.

About this study

The study will enroll 100 high risk tribe members and 20 low stroke risk tribe members. Each of these will be further studied for their atherosclerotic load by ultrasound measurements at the carotid bifurcation for presence of plaque as well as its stability or instability during pulsation. Enrolled participants will also receive assessment of biomarkers for stroke risk, including stroke-related vascular cognitive decline, an early and modifiable marker of TIA risk and serum analysis for glucose, cholesterol, microRNA and key proteins felt to be biomarkers of stroke.

The high risk participants will be randomized into two groups, and data analyzed by gender, age, history of cerebrovascular events, and the presence or absence of atherosclerosis in their carotid bifurcation including equal numbers of participants that in spite of high risk, have not yet deposited plaque.

  • One group will receive advice about standard therapy and information concerning risk factor guidelines to improve health awareness.
  • The other group will receive the same plus intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with at least quarterly individual face-to-face coaching meetings on lifestyle change and adherence to treatment.

At the end of 2-year follow-up, all groups will be reassessed for adherence to the program, atherosclerotic plaque progression or regression and its stability, serum biomarker response to therapy interventions, successful risk factor modification, vascular cognitive decline and incidence of stroke and TIA. Intention to treat analysis will estimate the efficacy of health coaching and will use G-estimation to correct for issues of non-compliance and discontinuation. Groups will be compared for change in both risk factors and outcomes.

Vascular cognitive decline is an important symptom of cerebrovascular disease which may precede a physical stroke with devastating results. Extensive preliminary data show that the frequency of this is surprisingly common in high risk patients and may predispose patients to later dementia. Vascular cognitive decline is a risk factor for stroke, but also is modifiable. A prior small study showed that intervention could stop the rate of decline. The study will see if this predicts participants at greatest risk for stroke that would improve with an intensive intervention program.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants receiving health care through the Oneida Health Council Program
  • Participants deemed to be at high risk for stroke by modified Framingham assessment of medical history, including cerebral cardiovascular symptomatology, hypertension, diabetes, smoking, BMI
  • Willingness to participate in the study, including two-year follow-up
  • Controls will be selected using the same criteria with the exception that upon screening, they are not deemed to be at high risk for stroke.

Exclusion criteria

  • Presence of established dementia
  • Inability to participate in physical and exercise programs due to preexisting disability
  • Illiteracy
  • Prior carotid procedure altering ultrasound finding
  • Presence of medical condition precluding participation or follow-up over a two-year period of time.

Treatment and study plan

High Risk - intensive coaching

Other

The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.

Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis.

High Risk - standard care

Other

The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.

Low Risk - control

Other

Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.

Primary outcomes

  1. Change in Incidence of Stroke or TIA

    Time frame: baseline and 2 years

    Number of incidences of stroke or TIA during the study

  2. Change in Number of Participants that meet AHA Simple Rules for Diastolic Blood Pressure

    Time frame: baseline and 2 years

    Number of Participants with diastolic blood pressure < 90 mmHg

  3. Change in Number of Participants that meet AHA Simple Rules for Systolic Blood Pressure

    Time frame: baseline and 2 years

    Number of Participants with systolic blood pressure < 140 mmHg

  4. Change in Number of Participants that meet AHA Simple Rules for Total Cholesterol

    Time frame: baseline and 2 years

    Number of Participants with total cholesterol < 200 mg/dL

  5. Change in Number of Participants that meet AHA Simple Rules for Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: baseline and 2 years

    Number of Participants with LDL-C < 100 mg/dL

  6. Change in Number of Participants that meet AHA Simple Rules for High Density Lipoprotein Cholesterol (HDL-C)

    Time frame: baseline and 2 years

    Number of Participants with HDL-C > 60 mg/dL

  7. Change in Number of Participants that meet AHA Simple Rules for Blood Sugar

    Time frame: Baseline and 2 years

    Number of Participants with A1c < 7.5

  8. Change in Number of Participants that meet AHA Simple Rules for Body Mass Index (BMI)

    Time frame: Baseline and 2 years

    Number of Participants who improve BMI

  9. Change in Number of Participants that meet AHA Simple Rules for Smoking Status

    Time frame: baseline and 2 years

    Number of Participants who Smoke

  10. Change in TabCAT Score

    Time frame: baseline and 2 years

    The Tablet-based Cognitive Assessment Tool will examine avorites (rote verbal learning and memory), match (processing speed), flanker (executive functions), and line orientation (visuospatial abilities).

  11. Change in Montreal Cognitive Assessment (MoCA) Vancouver Island Coastal First score

    Time frame: baseline and 2 years

    Montreal Cognitive Assessment will assess vascular cognitive decline

Secondary outcomes

  1. Change in Plaque Area

    Time frame: baseline and 2 years

    Measured via carotid ultrasound.

  2. Change in pulsatility index in carotid arteries

    Time frame: baseline and 2 years

    Measured via carotid ultrasound. This index is a unitless measurement calculated: peak systolic velocity - end diastolic velocity, divided by the mean velocity, higher values are thought to represent increased resistance to blood flow

  3. Correlation of carotid plaque grayscale texture features (grayscale median values [no units]) to stroke risk factors

    Time frame: baseline and 2 years

    Measured via carotid ultrasound

  4. Change in Circulating Dipeptidyl Peptidase (DPPIV)

    Time frame: Baseline and 2 years

    DPPIV is a circulating protein associated with cardiovascular risk. This will be measured via blood draw at baseline and 2 years.

  5. Change in Circulating Galectin3 (Gal-3)

    Time frame: baseline and 2 years

    Gal-3 is a circulating protein associated with cardiovascular risk. This will be measured via blood draw at baseline and 2 years.

Other outcomes

  1. Change in Serum microRNA

    Time frame: baseline and 2 years

    Levels of serum microRNA are associated with increased stroke risk. This will be measured via blood draw at baseline and 2 years.

  2. Compliance Rates

    Time frame: 2 years

    Number of people complying with study

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • Wisconsin Partnership Program

Registry information

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
May 11, 2020
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.